Liquidia (NASDAQ:LQDA) Director Sells $560,242.88 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 8,468 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $66.16, for a total value of $560,242.88. Following the sale, the director directly owned 44,637 shares of the company’s stock, valued at approximately $2,953,183.92. This trade represents a 15.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Raman Singh also recently made the following trade(s):

• On Friday, September 11th, Raman Singh sold 9,024 shares of Liquidia stock. The stock was sold at an average price of $68.62, for a total transaction of $619,226.88.

Liquidia Stock Down 0.1%

Shares of NASDAQ LQDA opened at $68.39 on Friday. The firm’s fifty day moving average is $76.40 and its 200 day moving average is $60.45. Liquidia Corporation has a 52 week low of $21.15 and a 52 week high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company has a market cap of $6.12 billion, a price-to-earnings ratio of 49.92 and a beta of 0.53.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) EPS. On average, equities research analysts expect that Liquidia Corporation will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on LQDA. Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday, June 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Lifesci Capital cut Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Wednesday, August 12th. Stephens set a $130.00 price objective on Liquidia in a research report on Friday, July 24th. Finally, HC Wainwright set a $36.00 target price on Liquidia in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $98.08.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new stake in Liquidia during the second quarter worth about $29,694,000. Bank of America Corp DE increased its stake in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in shares of Liquidia during the first quarter valued at approximately $9,337,000. T3 Companies LLC purchased a new position in shares of Liquidia during the fourth quarter valued at approximately $6,084,000. Finally, Eversept Partners LP boosted its position in shares of Liquidia by 33.0% in the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.